Applied BioMath, LLC announced their ongoing collaboration with Monte Rosa Therapeutics to develop a cellular systems pharmacology model for cereblon (CRBN)-based molecular glue degraders (MGDs) targeting GSPT1. The model will be used to predict and explain CRBN-based GSPT1 target degradation in various cellular disease settings and to answer mechanistic questions. Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Their approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.74 USD | -2.67% | +21.54% | -16.11% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.11% | 290M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+45.89% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Applied BioMath, LLC Announces Collaboration with Monte Rosa Therapeutics for Systems Pharmacology Modeling in Cereblon-based Molecular Glue Degraders